Document Detail


Novel gastroretentive controlled-release drug delivery system for amoxicillin therapy in veterinary medicine.
MedLine Citation:
PMID:  21198678     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Horwitz, E., Kagan, L., Chamisha, Y., Gati, I., Hoffman, A., Friedman, M., Lavy, E. Novel gastroretentive controlled-release drug delivery system for amoxicillin therapy in veterinary medicine. J. vet. Pharmacol. Therap. doi: 10.1111/j.1365-2885.2010.01255.x. Beta-lactam antimicrobials, commonly used in both veterinary and human medicine, generally present short biologic half-lives, whereas their activity is enhanced as pathogen exposure is prolonged. These properties necessitate multiple-dose regimens of standard dosage forms, thereby hampering pet owner adherence, frequently resulting in therapeutic failure. This study presents a novel controlled-release gastroretentive oral drug delivery system for beta-lactams with which single-dose administration provides an effective antimicrobial course, optimizing pharmacokinetic (PK)-pharmacodynamic (PD) profiles, minimizing adverse effects and emergence of antimicrobial resistance and facilitating adherence. Our prototype sustained-delivery swelling-tablet (SDST), based on a degradable hydrophilic polymeric matrix, was designed to enable continuous input of these drugs to their absorption sites over several days. Several SDST formulations of the beta-lactam amoxicillin were evaluated in in vitro dissolution studies. Two formulations were selected for further in vivo canine studies, for determination of gastric retention and PK-PD profiling. Prolonged gastric retention times maintaining allowed for maintained effective drug concentrations against many clinically relevant pathogens for more than 48 h for one formulation and more than 5 days for the other. Both SDST formulations offer significant advantages over standard immediate-release therapy in achieving PK-PD goals and enhancing adherence. The prototypical formulations represent a novel platform which may be modified to meet various clinical requirements.
Authors:
E Horwitz; L Kagan; Y Chamisha; I Gati; A Hoffman; M Friedman; E Lavy
Related Documents :
1067318 - Dmba and immunosuppression in the syrian golden hamster.
2605598 - Clinical pharmacology of sedatives and opioid analgesics, part i.
19388878 - Recent developments in the treatment of uveitis: an update.
2919338 - Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus eryth...
23798988 - The open access malaria box: a drug discovery catalyst for neglected diseases.
22123128 - Functional significance of genetic polymorphisms in p-glycoprotein (mdr1, abcb1) and br...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2010-12-28
Journal Detail:
Title:  Journal of veterinary pharmacology and therapeutics     Volume:  -     ISSN:  1365-2885     ISO Abbreviation:  -     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2011-1-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910920     Medline TA:  J Vet Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of fluoxetine on blood concentrations of serotonin, cortisol and dehydroepiandrosterone in ca...
Next Document:  A novel subcutaneous controlled-release amoxicillin degradable implant for extended-interval adminis...